Intuitive Surgical (ISRG) remains the robotic-assisted surgery market leader, with Q4 procedures up 18% and revenue rising 19% to $2.87 billion.

Recession fears have a way of making income investors second-guess everything, and if dividends are paid out of cash flow, and cash flow shrinks during economic downturns, it only seems logical that ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

On March 3, BofA analyst Jason Gerberry raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $253 from $227. It reiterated a Neutral rating on the shares.

Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Of all the retirement activities you can engage in, worrying about your financial security shouldn’t be one of them. Owning dividend-paying stocks can help you relax and enjoy a more comfortable life ...

I’m talking specifically about an overlooked opportunity in drug stocks, which are about to see the value of their R&D dollars get a big boost from AI. We’re going to tap in with an 8.8%-yielding ...

Pfizer’s PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. Image Source: Zacks ...

While these favorable trends and operational strengths are undeniable, the central question remains: is this fundamental ...

If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh ...

NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...